{"id":63354,"date":"2026-04-16T21:14:44","date_gmt":"2026-04-16T13:14:44","guid":{"rendered":"https:\/\/flcube.com\/?p=63354"},"modified":"2026-04-16T21:14:45","modified_gmt":"2026-04-16T13:14:45","slug":"sino-biopharmaceutical-initiates-phase-iii-trial-of-lm-302-adc-combined-with-anti-pd-1-for-cldn18-2-positive-gastric-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63354","title":{"rendered":"Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer"},"content":{"rendered":"\n

Sino Biopharmaceutical Ltd<\/strong> (HKG: 1177<\/a>) has announced the enrollment of the first patient in a Phase III regulatory study<\/strong> evaluating LM-302<\/strong>, its CLDN18.2-targeted antibody-drug conjugate (ADC)<\/strong>, in combination with an anti-PD-1 monoclonal antibody<\/strong> as a first-line treatment<\/strong> for CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (GC\/GEJ)<\/strong>. The trial represents a strategic “ADC + immunotherapy” combination approach designed to achieve deeper tumor remission through synergistic mechanisms of action.<\/p>\n\n\n\n

Clinical Development Framework<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Study Phase<\/strong><\/td>Phase III (pivotal regulatory trial)<\/td><\/tr>
Patient Population<\/strong><\/td>First-line CLDN18.2-positive locally advanced or metastatic GC\/GEJ<\/td><\/tr>
Combination Therapy<\/strong><\/td>LM-302 (CLDN18.2 ADC) + anti-PD-1 monoclonal antibody<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Progression-free survival (PFS) and overall survival (OS)<\/td><\/tr>
Trial Status<\/strong><\/td>First patient enrolled \u2013 active recruitment<\/td><\/tr>
Regulatory Pathway<\/strong><\/td>Designed to support marketing authorization in China and global markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile \u2013 LM-302<\/h2>\n\n\n\n